Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, to ask the Secretary of State for Health and Social Care, what steps is his Department taking to increase the NICE cost-effectiveness thresholds for new medicines and increase the value that the UK places on medicines.

The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.

Tens of thousands of NHS patients will benefit from a landmark trade deal between the United Kingdom and the United States, which will secure and expand access to vital drugs, safeguard our medicines supply chain, and drive crucial investment while supporting UK patients and industries. This agreement will increase the amount which the United Kingdom pays for life-changing medicines by 25%, ensuring faster patient access for vital medicines for cancer, rare diseases, and other conditions.

A 25% increase in medicine pricing corresponds to two changes to the way the National Institute for Health and Care Excellence evaluates medicines, specifically a change to the standard cost effectiveness threshold and the introduction of a new value set for judging health states.